Protagenic Financials
This page shows Protagenic (PTIXW) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Protagenic passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Protagenic generates $0.76 in operating cash flow (-$4.2M OCF vs -$5.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Protagenic generated $0 in revenue in fiscal year 2024.
Protagenic's EBITDA was -$5.7M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 25.6% from the prior year.
Protagenic reported -$5.5M in net income in fiscal year 2024. This represents a decrease of 10.5% from the prior year.
Protagenic earned $-1.13 per diluted share (EPS) in fiscal year 2024. This represents an increase of 1.7% from the prior year.
Protagenic held $80K in cash against $0 in long-term debt as of fiscal year 2024.
Protagenic had 517,257 shares outstanding in fiscal year 2024. This represents a decrease of 88.3% from the prior year.
Protagenic's ROE was 166.5% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is up 302.8 percentage points from the prior year.
Protagenic invested $3.8M in research and development in fiscal year 2024. This represents an increase of 25.5% from the prior year.
PTIXW Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | $0 | $0 | N/A | $0 | $0 | $0 |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $154K-43.7% | $273K-30.7% | $394K-55.2% | $880K+554.2% | $135K+693.3% | $17K-11.3% | $19K-98.7% | $1.5M |
| SG&A Expenses | $155K-3.2% | $160K-8.7% | $175K-69.1% | $568K+1042.4% | $50K+125.6% | $22K-7.2% | $24K-91.4% | $278K |
| Operating Income | -$925K+16.9% | -$1.1M+52.5% | -$2.3M-61.9% | -$1.4M-260.8% | -$401K-13.0% | -$355K-10.4% | -$322K+81.5% | -$1.7M |
| Interest Expense | $24K-30.6% | $34K+114.4% | -$239K | N/A | -$449K-88.0% | -$239K | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | -$3K-200.0% | $3K | N/A |
| Net Income | $2.2M+354.3% | -$869K+82.8% | -$5.1M-251.2% | -$1.4M-69.4% | -$850K-46.0% | -$582K-79.6% | -$324K+81.2% | -$1.7M |
| EPS (Diluted) | $1.14+342.6% | $-0.47+65.7% | $-1.37 | $-2.75 | $-0.16 | $-0.11-83.3% | $-0.06+98.9% | $-5.44 |
PTIXW Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $4.4M-11.4% | $5.0M-22.9% | $6.5M+7182.5% | $89K-95.4% | $2.0M+29.7% | $1.5M+2.8% | $1.5M-43.1% | $2.6M |
| Current Assets | $2.3M-19.6% | $2.9M-34.0% | $4.3M+4761.2% | $89K-95.3% | $1.9M+32.3% | $1.4M+3.9% | $1.4M-44.5% | $2.5M |
| Cash & Equivalents | $2.2M-18.7% | $2.7M-33.5% | $4.1M+28089.3% | $15K-81.7% | $80K+11.4% | $71K-90.0% | $714K+43815.5% | $2K |
| Inventory | $1K-0.1% | $1K-1.8% | $1K+5.5% | $1K | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $6.8M-29.7% | $9.7M-7.3% | $10.5M+107.5% | $5.0M-4.4% | $5.3M+32.5% | $4.0M+23.6% | $3.2M-26.3% | $4.4M |
| Current Liabilities | $6.8M-29.7% | $9.7M-7.3% | $10.5M+107.5% | $5.0M+434.8% | $943K+19.4% | $789K+17.0% | $675K+51.2% | $446K |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$2.4M+49.1% | -$4.7M-18.3% | -$4.0M+19.8% | -$5.0M-49.3% | -$3.3M-34.3% | -$2.5M-40.9% | -$1.8M+2.0% | -$1.8M |
| Retained Earnings | -$9.1M+19.5% | -$11.3M-8.3% | -$10.5M-93.7% | -$5.4M+85.1% | -$36.3M-4.5% | -$34.7M-1.9% | -$34.1M-4.9% | -$32.5M |
PTIXW Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$510K+63.5% | -$1.4M-19.5% | -$1.2M-9.3% | -$1.1M-30.3% | -$820K-341.6% | -$186K+24.7% | -$246K+85.1% | -$1.7M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $0 | $0-100.0% | $943K | N/A | $0 | $0-100.0% | $1.6M+33.0% | $1.2M |
| Financing Cash Flow | -$2+100.0% | -$15K-100.3% | $4.4M+4214.3% | $103K-93.6% | $1.6M+405.4% | $317K-67.1% | $963K | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
PTIXW Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -92.4%-110.9pp | 18.5%-108.8pp | 127.3%+98.2pp | 29.1%+3.4pp | 25.6%+2.1pp | 23.6%+5.1pp | 18.5%-77.9pp | 96.4% |
| Return on Assets | 49.9%+67.3pp | -17.4%+60.6pp | -78.0%+1538.3pp | -1616.3%-1572.8pp | -43.5%-4.9pp | -38.6%-16.5pp | -22.1%+44.8pp | -66.9% |
| Current Ratio | 0.34+0.0 | 0.29-0.1 | 0.41+0.4 | 0.02-2.0 | 2.00+0.2 | 1.80-0.2 | 2.03-3.5 | 5.53 |
| Debt-to-Equity | -2.85-0.8 | -2.06+0.6 | -2.63-1.6 | -1.02+0.6 | -1.59+0.0 | -1.61+0.2 | -1.84+0.6 | -2.44 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$3.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Frequently Asked Questions
What is Protagenic's annual revenue?
Protagenic (PTIXW) reported $0 in total revenue for fiscal year 2024. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Protagenic profitable?
No, Protagenic (PTIXW) reported a net income of -$5.5M in fiscal year 2024.
What is Protagenic's earnings per share (EPS)?
Protagenic (PTIXW) reported diluted earnings per share of $-1.13 for fiscal year 2024. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Protagenic's EBITDA?
Protagenic (PTIXW) had EBITDA of -$5.7M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Protagenic's return on equity (ROE)?
Protagenic (PTIXW) has a return on equity of 166.5% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is Protagenic's operating cash flow?
Protagenic (PTIXW) generated -$4.2M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Protagenic's total assets?
Protagenic (PTIXW) had $2.0M in total assets as of fiscal year 2024, including both current and long-term assets.
How much does Protagenic spend on research and development?
Protagenic (PTIXW) invested $3.8M in research and development during fiscal year 2024.
How many shares does Protagenic have outstanding?
Protagenic (PTIXW) had 517,257 shares outstanding as of fiscal year 2024.
What is Protagenic's current ratio?
Protagenic (PTIXW) had a current ratio of 2.00 as of fiscal year 2024, which is generally considered healthy.
What is Protagenic's debt-to-equity ratio?
Protagenic (PTIXW) had a debt-to-equity ratio of -1.59 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Protagenic's return on assets (ROA)?
Protagenic (PTIXW) had a return on assets of -282.5% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Protagenic's cash runway?
Based on fiscal year 2024 data, Protagenic (PTIXW) had $80K in cash against an annual operating cash burn of $4.2M. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Protagenic's debt-to-equity ratio negative or unusual?
Protagenic (PTIXW) has negative shareholder equity of -$3.3M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Protagenic's Piotroski F-Score?
Protagenic (PTIXW) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Protagenic's earnings high quality?
Protagenic (PTIXW) has an earnings quality ratio of 0.76x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.